IMMUNOGLOBULIN IGG1, ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE SCT400 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SCT400 .KAPPA.-CHAIN, DIMER

B-cell Non Hodgkin's Lymphoma

Sinocelltech Ltd.monoclonal_antibodyPhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

317 Active assets in the B-cell Non Hodgkin's Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINDESINE Children's Cancer Group, China	Phase 4	BBB
cc-5013 Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Odronextamab University of Birmingham	Phase 3	BBB
METHOTREXATE Children's Cancer Group, China	Phase 4	BBB
Cytosin-Arabinosid Children's Cancer Group, China	Phase 4	BBB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN IGG1, ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE SCT400 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SCT400 .KAPPA.-CHAIN, DIMER is also rated in:

diffuse large B-cell lymphomaDormant

CCC

Indicative ·

54 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →